Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy

dc.contributor.authorCarter, P.en_US
dc.contributor.authorAlifrangis, C.en_US
dc.contributor.authorCereser, B.en_US
dc.contributor.authorChandrasinghe, P.en_US
dc.contributor.authorDel Bel Belluz, L.en_US
dc.contributor.authorFotopoulou, C.en_US
dc.contributor.authorFrilling, A.en_US
dc.contributor.authorHerzog, T.en_US
dc.contributor.authorModerau, N.en_US
dc.contributor.authorTabassum, N.en_US
dc.contributor.authorKrell, J.en_US
dc.contributor.authorStebbing, J.en_US
dc.date.accessioned2018-03-07T07:51:56Zen_US
dc.date.available2018-03-07T07:51:56Zen_US
dc.date.issued2017en_US
dc.descriptionIn Pubmeden
dc.description.abstractTumor molecular profiling has enabled selection of targeted therapies in a host of solid tumors. Here we used a retrospective clinical cohort, to evaluate the benefit of tailoring treatments for female genital tract malignancy, using tumor molecular profiles. Clinical outcome data for 112 patients was retrospectively separated into two groups. These either followed a matched treatment plan that incorporated at least one drug recommended according to their tumor profile and none that were expected to have no benefit (64 patients), or was unmatched with suggested treatments and received at least one drug that was anticipated to lack benefit for that tumor (48 patients). In the group of patients whose drugs matched those recommended by molecular profiling of their tumor, their overall survival was 593 days on average, compared to 449 days for patients that did not; removing drugs predicted to have no benefit from treatment regimens received after profiling increased survival by 144 days on average (P = 0.0265). In the matched treatment group, 30% of patients had died by the last time of monitoring, whereas this was 40% in the unmatched group (P = 0.2778). The IHC biomarker for the progesterone receptor was demonstrated to be prognostic for survival.en_US
dc.identifier.citationOncotarget.2017; 9(5):6007-6014 (Erratum in :Oncotarget. 2018; 9(19):15164)en_US
dc.identifier.issn1949-2553 (Electronic)en_US
dc.identifier.issn1949-2553 (Linking)en_US
dc.identifier.urihttp://repository.kln.ac.lk/handle/123456789/18612en_US
dc.language.isoen_USen_US
dc.publisherImpact Journalsen_US
dc.subjectCancer treatmenten_US
dc.titleAssessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancyen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
oncotarget-09-6007.pdf
Size:
1.16 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
52 B
Format:
Item-specific license agreed upon to submission
Description: